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Genetic backgrounda b s t r a c t
The crucial event in the course of malignancies such as breast cancer is its metastatic spread from the
primary tumor of origin to distant organs. The natural history of a tumor is determined by the expression
of its genes, and in this sense, knowledge has advanced dramatically in recent decades. However, much
less is known about the role that the patient plays in the behavior of a tumor. In this article, we review the
evidence regarding the genetic background of the host in metastatic tumor dissemination, providing
information from epidemiological studies as well as from animal models and human studies. Undoubt-
edly, the elucidation of possible interpersonal variability in susceptibility to developing metastases
would signiﬁcantly contribute to improve management of cancer patients.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Up to 90% of cancer deaths are due to complications arising
from metastatic dissemination of the disease [1]. Metastasis is
an extraordinarily complex process, entailing tumor cells acquir-
ing a set of features that allow them to develop new foci of the
disease. Among such characteristics are rupturing of the basal
membrane, loss of different intercellular junctions, migratory
capacity from the primary tumor site or through the extracelluce,
the mechanisms triggering the invlar matrix, incorporation into
the blood or lymphatic stream and, ultimately, extravasation of
tumor cells into the parenchyma of the secondary organ. Despite
their importance, the mechanisms triggering the invasion
metastasis cascade and the factors regulating these processes
are not yet fully understood, and several different models have
been proposed to explain the phenomena underlying tumor
dissemination.Models of metastatic growth
The most widely accepted theory is the progression or clonal
selection model, proposed originally by Nowell [2]. According to
this theory, only a small fraction of the tumor cells acquire the
metastatic phenotype, through a series of somatic mutations as a
late event in the course of the tumor. This theory is supported by
Fidler’s [3,4] experiments, in which B16 melanoma cells were in-
jected into mice that developed pulmonary metastases. The meta-
static capability of tumor cells sampled from the metastasis was
seen to be greater than that of cells from the primary tumor. These
results led to the suggestion that most of the primary tumor’s cells
had low metastatic potential. Therefore, they had acquired the
metastatic phenotype during their development through addi-
tional somatic mutations. This model, based on cultured cell lines,
has not been proved in other similar models in which the meta-
static capacity of cells derived from metastatic foci was similar to
that seen in the primary tumor cells [5,6]. Furthermore, the exis-
tence of cancer of unknown-primary site is against this theory. In
these patients, the metastases are present at the onset of clinic dis-
ease without a primary tumor with enough larger size (i.e. number
of cells) to achieve the required mutational events for the meta-
static phenotype acquisition.
In an attempt to explain these observations that the dissemina-
tion capacity of the cells from secondary foci was not greater than
that of the primary tumor cells, Weiss proposed another model
called dynamic or compartmental heterogeneity [7]. Unlike the
294 N. Ribelles et al. / Cancer Treatment Reviews 40 (2014) 293–299clonal selection model, all the cells in a tumor would have the
capacity to generate metastases, but due to epigenetic changes
only a small portion of these cells would be able to complete the
process of dissemination at a given moment in time. Some studies
support Weiss theory, showing that methylation inhibitors are able
to induce the development of metastatic phenotypes in mouse
models [8,9]. However, given that methylation inhibitors can cause
chromosomal impairments, the capacity to produce metastases
after treatment with these agents may be due to mutational phe-
nomena and not to real epigenetic changes [10].
Some of the capabilities that tumor cells must acquire to devel-
op a distant focus are characteristics inherent to normal lymphoid
cells such as proteolytic degradation or intra- and extravasation
capabilities. Accordingly, the fusion model maintains that tumor
epithelial cells would acquire such properties by incorporating
DNA from lymphoid cells [11]. In physiological conditions, there
are some examples of cellular fusion phenomena, like multinucle-
ate skeletal muscle ﬁbers derived from myocytes fusion. Moreover,
some data from cell and animal models, as well as from human tu-
mors, show that host and tumor cells do merge. Two cases of renal
cell tumors have been reported in patients who received bone-
marrow transplantations, containing both the patients’ own and
the marrow donors’ DNA [12,13]. Also, in myeloma patients the
presence of chromosomal translocations speciﬁc for myeloma has
been identiﬁed in normal osteoclasts [14]. It is not clear, however,
whether these ﬁndings play a role in the development of a meta-
static phenotype or whether they are just a late event with no cau-
sal effect.
The metastasis gene transfer model provides a different ap-
proach. Here, metastases do not originate from circulating tumor
cells, but instead from incorporating tumor DNA into circulating
stem cells located in the target organ [15]. There are only experi-
mental scant data to support this model of tumor dissemination,
like murine tumors developed from normal ﬁbroblasts in which
H-ras (V12) and c-myc oncogenes have been taken up from apop-
totic bodies [16].
Based on existing data about the role of stem cells in breast can-
cer tumorigenesis [17], some authors have maintained that only
tumor stem cells are capable of initiating new metastatic foci.
According to this model, if the malignant switch starts in stem
cells, then tumors with poor prognosis and high metastatic capa-
bilities will develop. However, if the transformation occurs in more
highly evolved progenitor cells, then the neoplasm would have a
more limited potential to generate distant foci [18]. These stem
cells would be highly resistant to chemotherapy.
Many studies conducted since the 1990s using microarrays
techniques have conﬁrmed that tumors can be distinguished
through their gene expression proﬁles, enabling us to determine
whether primary tumors have the capacity to trigger metastases
[19]. These data imply that the vast majority of tumor cells from
the primary site have sufﬁcient genetic information to develop
metastases. Based on these ﬁndings, different groups have sug-
gested that metastatic ability is an event occurring during the ini-
tial stages of oncogenesis and is conditioned by the same
mutational events that may be involved in primary tumorigenesis
[20]. Furthermore, Ramaswamy’s group has also deﬁned a set of 17
genes linked to metastatic phenotypes, regardless of the primary
tumor origin [21]. The clonal dominance model is another interpre-
tation of this theory, which states that the number of primary tu-
mor cells with a metastatic phenotype progressively increases
until they become the dominant population. Thus, most cells
would be capable of initiating distant foci at a given moment in
time [22].
All these models and theories share the common belief that it is
mainly the tumor’s characteristics that govern its capability for
metastases. However, this is a complex biological phenomenonthat involves both tumor cells (seed) and normal cells in the blood-
stream and in the different target organs (soil). The ﬁndings by
Massagué’s group reveal the reality of this organ tropism, deﬁned
by Paget in the 19th century [23]. According to these results, there
are different tumor cell subpopulations with different afﬁnities to
colonize certain target organs, depending on their genetic constitu-
tion. Tumor cells that overexpress the CXCR4, PTHLH, IL11, MMP1
and OPN genes have the ability to promote bone metastases [24],
while cells that overexpress COX, EREG and ANGPTL4 exhibit a tro-
pism for the lung [25]. In addition, tumor cells overexpressing
ST6GALNAC5, COX2, HBEGF and ANGPTL4 have a particular afﬁnity
for colonizing the central nervous system [26]. Presumably, the
gene patterns speciﬁc to each of these cell subpopulations may
be obtained through a series of somatic changes [27].
Cells from host’s immune system also play a key role in modu-
lating the tumor microenvironment. Several innate and adaptative
immune cell types, effector molecules and pathways can some-
times function as extrinsic tumor-suppressor mechanisms [28].
However, tumors develop even in presence of an intact immune
system and become eventually clinically detectable. That occurs
because the immune system plays a dual role in cancer: it not only
suppresses tumor growth but also promotes tumor progression by
selecting more aggressive tumor variants to survive in an immuno-
competent host or by modulating the tumor microenvironment in
order to facilitate tumor outgrowth [29]. Thus, the differences in an
individual’s immune repertoire, the antigens processing and pre-
senting capacity, the generation of tumor antigens and the ability
of cancer to suppress immune response will determine the overall
outcome of a particular tumor in an individual [30].Genetic predisposition model
Over the last decade, many published papers have stressed the
importance of cells from tumor stroma, both in primary tumori-
genesis and in the process of metastasis. The contributions made
by different host-cell types, that comprise the tumor microenvi-
ronment, are integrated within a system of heterotypic signalling
interactions that enable the acquired capacity for invasive growth
and metastatic dissemination [28]. These data provide a broader
view of the inﬂuence of these host characteristics on the course
and behavior of the neoplasm. According to the premises of the ge-
netic predisposition model, the patient’s germline genetic burden
would also be involved in the expression of the metastatic pheno-
type of a tumor, just as constitutional polymorphisms are respon-
sible for expressing other features or characteristics of the
individual.Animal studies
Hunter’s group showed in mouse models that the metastatic
behavior of a tumor induced by the same oncogenic event, the
antigen of the polyoma T virus, differed according to the germline
genetic burden for each of the strains used (Fig. 1). The FVB/NJ
mouse strain constitutionally expressed the oncogene of the poly-
oma T virus, which induced the development of highly aggressive,
multiple and synchronous breast tumors in almost all virgin fe-
males, with over 85% of the animals developing pulmonary metas-
tases at 100 days of life [31]. In successive experiments by this
group, male FVB/NJ mice were mated with different homozygotic
strains of female mice, and the density of lung metastases was
studied in the F1 progeny. The authors found that there was signif-
icant variation in the density of lung metastases according to the
female mouse strain used. For instance, and taking the pulmonary
density present in the F1 progeny from the FVB/NJ strain as a ref-
erence, the density of metastases in the progeny of the DBA/2J
Fig. 1. Different outcomes can be observed secondary to the same primary oncogenic event depending on the mouse strain used. Therefore, the only variation is the genetic
background on which tumor developed. The unique primary oncogenic event comes from male FVB/NJ, transgenic mice that express the mouse polyoma middle-T antigen
which induced the development of palpable mammary tumors by 60 days of life, and pulmonary metastases after 100 days in 85–95% of the animals. Different genetic
background derived from twenty-eight different strains of homozygous, inbred female mice. Males FVB/NJ were mated with inbred female animals to produce transgene-
positive F1 hybrid female progeny. These virgin transgene-positive F1 hybrid females were euthanized at 100 days and the density of pulmonary metastases was determined.
As the maternal genome was the only difference in the different outcrosses, the most likely explanation for the observed variation in the metastatic capacity of the progenies
studied must be the existence of different combinations of germ line polymorphisms present in each of the different F1 hybrid progenies. These germ line variations may
modulate de ability of tumor cells to develop a metastatic phenotype. (Modiﬁed from Ref. [33].)
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1.5 times higher [32,33]. In later studies, the authors identiﬁed cer-
tain genes supposedly related to the efﬁciency of the metastatic
process in mice. These genes were identiﬁed as Sipa 1, Brms1,
Brd4 or Rrp1b and were located on chromosomes 7, 9 and 17
[34]. They seem to be involved in tumor suppression mechanismsor regulation of extracellular matrix expression [35–37]. In one of
their most recent studies, this group observed that gene expression
proﬁles for breast tumors in mice models were quite a mixture of
somatic and germline variants, including both the genetic back-
ground from tumor epithelium and inﬁltrating nonneoplastic tis-
sues [38].
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Further evidence supporting a possible hereditary component
in the expression of a tumor’s metastatic phenotype has been de-
rived from several Swedish epidemiological studies (Table 1). In
the ﬁrst of these studies, all women with breast cancer diagnosed
in Sweden between 1961 and 2001 were included. There were
identiﬁed 2787 pairs of mother–daughter cancer patients as well
as 831 cancer pairs amongst siblings. Cause-speciﬁc survival at
5 years was 87% for daughters whose mothers died during the ﬁrst
5 years after diagnosis, compared with 91% for women with moth-
ers surviving at 5 years post-diagnosis (p = 0.03). The relative risk
of death speciﬁcally from breast cancer during the ﬁrst 5 years
for a relative of a women with a poor prognosis was 1.6 (95% CI
1.2–2.2), after adjusting the data for other factors, such as age
and date of diagnosis, age at ﬁrst pregnancy, socioeconomic level
or geographic area of diagnosis. Between siblings, cause-speciﬁc
survival at 5 years for a woman whose older sister died of the dis-
ease during the ﬁrst 5 years post-diagnosis was 70%, compared to
88% for sisters whose proband was alive after 5 years (p = 0.01)
[39]. A further analysis from the same registry showed that 10-year
survival from breast cancer for daughters with mothers surviving
over 10 years was 86%while, for women whose mothers had died
in the ﬁrst 3 years, the 10-year survival dropped to 79%
(p = 0.03). The results from a reverse analysis were similar. The
mothers with daughters who had survived over 10 years had a spe-
ciﬁc breast-cancer survival rate of 63%, compared with 49% among
mothers whose daughters died during the ﬁrst 3 years post-diag-
nosis (p = 0.03). This effect was equally robust in both types of
analysis given that, after adjusting for other factors, the relative
risk of death from breast cancer for a daughter whose mother
had a good prognosis was 0.65 (95% CI 0.46–0.92), and the relative
risk for a mother with a good-prognosis daughter was 0.68 (95% CI
0.50–0.93) [40]. A new study from the Swedish Family-Cancer
Database was published recently, comparing data for family cases
divided into two groups: fatal cancer if the mother’s cause of death
was breast cancer and non-fatal cancer if the mother had died from
any other cause. Most women with breast cancer were diagnosed
after their mother’s death, although this proportion was greater
in fatal cancer cases (81%) than in the non-fatal cancer group
(56%). The risk of death for daughters whose mothers had died
from breast cancer was 1.97, in comparison to 1.51 for daughters
whose mothers had died from other causes, with a hazard ratio
of 1.3 between the two groups (p = 0.02) [41]. Similar data have
also been seen in other tumors, such as colorectal or prostate
cancer [41,42]. The main strength of these studies is the number
of patients prospectively included from all cases registered in the
country, together with the fact that information has been system-Table 1
Hazard rates for death for individuals with family history of breast cancer according to re
References Period of breast cancer diagnosis Family relations
Hartman (2007) [39] 1961–2001 Mother & daugh
Sisters
Combined
Hemminki (2008) [40] 1990–1999 Mother & daugh
Hemminki (2011) [41] 1958–2000 Mother & daugh
Lindstrom (2007) [42] 1961–2001 Mother & daugh
RR: relative risk.
a Mother as proband.
b Older sister as proband.
c Daughter as proband.atically compiled for family aggregation. One possible explanation
of these ﬁndings is the similarity in the diagnostic process or the
use of mammography screening among family members. However,
this explanation seems unlikely because adjustments were made
in the multivariate analysis for socioeconomic level or the resi-
dence place, apart from the fact that the Swedish public health sys-
tem has universal coverage. Obesity may also play a role in these
ﬁndings, given its involvement in breast cancer prognosis [43].
Another recent study performed in Geneva showed similar re-
sults. Data were taken from the Geneva Cancer Registry, which re-
cords all cancer events since 1970. Trained registrars
systematically abstracted accurate data from all hospitals, pathol-
ogy laboratories and private practitioners. In this study 160 pro-
bands and ﬁrst degree relatives (FDR) diagnosed with breast
cancer (117 mother–daughter pairs and 43 sister–sister pairs)
where analyzed, basing all analysis in breast cancer-speciﬁc mor-
tality. FDRs where categorized into familial groups by using the
Martingales residuals of the adjusted Cox model. Thus, they de-
ﬁned a good, medium and poor family prognosis group as the ﬁrst,
second and third tertile of the Martingale residual distribution,
respectively. Then, they estimated the breast cancer-speciﬁc stan-
dardized mortality ratios (SMRs) of FDRs in each family prognosis
group and made an univariately comparison of patient, tumor and
treatment characteristics of probands and their FDRs and between
FDRs. The analysis showed that patients grouped in the poor family
prognosis group had a 19-fold higher risk of death from breast can-
cer compared to the Geneva population (SMR 18.7, 95% CI 3.4–
20.4), whereas this risk was increased just by a 9-fold in the good
family prognosis group (SMR 9.4, CI 95% 1.4–16.4).
These results conﬁrmed the ones from the Swedish studies, sug-
gesting that breast cancer prognosis cluster within families, and
the inherited background is independent of patient, tumor charac-
teristics and treatment received.
This clustering may be explained by the inheritance of host and
tumor characteristics that determine survival, treatment response,
familial clustering in lifestyle or health-seeking behavior [44].
Human genetic studies
Once the evidence of possible hereditability for breast cancer
prognosis has been suggested by epidemiological studies, we need
to understand the mechanisms underpinning this phenomenon.
We should consider as plausible the possibility that tumor behav-
ior could be conditioned by some genetic control from the germ-
line. First, just as a high risk of incidence is inherited, the nature
of the tumor regarding aggressiveness and metastasizing capabil-
ity could also be transmitted. For instance, between 57% and 80%
of women carrying BRCA1 mutations develop triple-negative phe-latives’ outcome.
hip n Breast cancer death RR 95% CI p
Good vs. poor prognosis
ter 2787 pairs 1.6a 1.1–2.3 0.006
831 pairs 1.8b 1.0–3.4 0.06
3618 pairs 1.6a,b 1.2–2.2 0.002
Poor vs. good prognosis
ter 1277 pairs 0.65a 0.46–0.92 0.02
0.68c 0.50–0.93 0.02
Non-fatal vs. fatal cancer
ter 4841 pairs 1.3a 1.1–1.54 0.002
Good vs. poor prognosis
ter 2162 pairs 1.75 1.13–2.71 0.01
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subtype of breast cancer has been associated with early relapse
and poor prognosis [47]. Data derived from different population
studies have not been showed differences in incidence among
the breast-cancer subtypes in cases with a family history [48–51]
(Table 2). Only Yang’s paper [51], including patients under the
age of 40 years old, reported a higher risk of incidence of triple neg-
ative cases, although there were no statistically signiﬁcant differ-
ences. However, these studies do not help to elucidate whether
the nature of the tumor may be an inherited feature, because none
of them includes an analysis of the possible correlations of differ-
ent breast cancer subtypes incidence among family relatives.
There is, however, another possible explanation for the ﬁndings
from the Swedish Family-Cancer Database epidemiological studies.
It might be possible that the inherited trait was a greater or lesser
susceptibility of the individual for the development of metastases.
In this respect, data have been published concerning the associa-
tion of certain germline polymorphisms and the likelihood of
developing metastases in breast cancer patients. Most of these
studies have considered different polymorphisms using a candi-
date gene approach showing signiﬁcant associations between the
different allelic forms and worse tumor behavior in carrier
patients, after adjusting the survival analysis for other universally
accepted variables [36,37,52–70]. Some of these polymorphisms
are located in the LIG4 [58], Rrp1b [36], SIPA1 [60], R72P [67],
GPX4 [68], CCND3 [53], CHEK2 [71] or NQO1⁄2 genes [57]. The
magnitude of the recurrence or death hazard ratios (HR) reported
in these studies is quite limited, ranging between 0.46 and 2.51.
Nevertheless, for the NQO1⁄2 variant, the relative risk of metastasis
was 10 times greater in the homozygotic carriers who also had a
tumor with mutated p53 protein and who had received anthracy-
cline-based adjuvant chemotherapy [57]. Nevertheless we cannot
assume that the effect of each single nucleotide polymorphism
(SNP) is individual, it is the result of an interaction between differ-
ent genetic variants. For instance, it has been suggested a signiﬁ-
cant dose-dependent effect of PRKAG2-02 (a gen involved in TP53
regulatory network) on breast cancer survival conﬁned to MDM2
SNP309 (TG/GG) carriers [72]. Some authors suggest that the effect
of certain SNPs on survival could be due to a better response to a
speciﬁc treatment. Jamshidi et al. showed an improved overall sur-
vival for PPP2R2B rare A allele compared to GG genotype carriers
only in patients who had received adjuvant hormonal therapy. This
study did not show correlations with breast cancer subtype [72].
As in other studies using the candidate-gene approach, all these
data should be considered with caution because the biological
pathways involved in the process of metastatic dissemination are
not enough well understood for appropriate gene selection. Fur-
thermore, the levels of signiﬁcance obtained in some of these asso-
ciations, although correct at conventional levels, would not attain
the signiﬁcance level suggested as appropriate for studies on gene
association with the candidate gene approach (p < 0.0001) [73].
Therefore, it is likely that the differences observed could be, in fact,
false positives that would not allow the reproducibility of such re-Table 2
Association between incidence family history and breast cancer subtypes.
Subtype deﬁnition Luminal A Lumin
HR 95% CI HR
Yang (2007) [51] Five markersa 1.72 1.21–2.45 2.31
Millikan (2008) [48] Five markersa NA NA 1.1
Welsh (2009) [50] Three markersb 1.78 1.42–2.23 2.10
Phipps (2011) [49] Three markersc 1.62 1.54–1.70 NA
NA: not available.
a Luminal A (ER+ and/or PR+, HER2), Luminal B (ER+ and/or PR+, HER2+), HER2 (ER
b Luminal A (ER+ and/or PR+, HER2), Luminal B (ER+ and/or PR+, HER2+), HER2 (ER
c Luminal A and Luminal B were grouped as ER+, HER2 (ER, PR, HER2+) and triplesults [74]. In an attempt to overcome these limitations, Pharoah’s
group published two ambitious studies using a genome-wide asso-
ciation study (GWAS) approach. In the ﬁrst study, the relationship
between 10,621 germline polymorphisms and survival was studied
in 3761 breast-cancer patients. Herein, they identiﬁed a polymor-
phism at the OCA2 gene, a rare variant of which may be associated
with enhanced all-cause survival in patients with negative estro-
gen receptor tumors. This outcome was conﬁrmed in another val-
idation series of 14,096 patients, although the level of signiﬁcance
did not reach the required level for GWAS studies (p = 5  108) in
either initial analyses or in the combined dataset [75]. In the sec-
ond paper, 528,252 polymorphisms were studied in 1145 breast-
cancer patients, and it was not possible to identify any common
germline polymorphism associated with breast cancer survival.
Afterwards, the authors studied the ten most signiﬁcant polymor-
phisms from the ﬁrst stage in another cohort of 4335 patients,
obtaining the same disappointing results [76]. More promising re-
sults come from a recent study performed in a 2-stage GWAS
among 6110 patients from an asiatic cohort with stage I–IV breast
cancer. In the discovery stage, 49 SNPs associated with overall
mortality were selected from 1950 breast-cancer patients. These
49 SNPs were evaluated in an independent replication stage with
4160 patients. Two SNPs, rs3784099 on chromosome 14 and
rs9934948 on chromosome 16, were found to be associated with
overall mortality and with recurrence. The ﬁrst SNP is located in
the RAD51L1 gene, an established cancer susceptibility gene. Fur-
thermore, this SNP is associated with a differential expression of
a couple of genes involved in breast cancer progression, SNCG
and CTF1, providing additional support for the association between
this SNP and breast cancer outcome observed in the study.
Rs9934948, the other SNP associated with overall mortality in this
cohort of patients, was also strongly correlated with overall mor-
tality in a second validation stage performed among breast cancer
survivors of European ancestry, demonstrating its generalizability
to other ethnic groups.
This SNP is located on chromosome 16 and resides nearby the
gene PSMD7, which activity is increased in tumor cells. These data
suggest a possible role for this SNP in breast cancer prognosis
although the level of signiﬁcance did not reach the required level
for GWAS studies [77].
To improve the statistical power to detect common genetic vari-
ants associated with breast cancer prognosis, Raﬁq et al. performed
a 2-stage study in which the discovery stage was enriched with pa-
tients selected from survival extremes. The overall sample con-
sisted on breast cancer patients who were under 40 years at the
time of diagnosis, selected due to the worse outcome and its poten-
tial relation with a greater genetic component.
The discovery stage was formed by two groups selected from
the overall sample, one enriched for triple negative breast cancer
patients and the other for either very short (<2 years) or relatively
long duration (>4 years) of breast cancer speciﬁc survival.
After the discovery stage, 35 of the best 50 SNPs showing asso-
ciation with prognosis were genotyped in a validation group ofal B HER2 Triple negative or basal-like
95% CI HR 95% CI HR 95% CI
0.88–6.08 2.35 1.03–5.38 3.17 1.69–5.92
0.7–1.8 0.9 0.5–1.6 1.0 0.7–1.5
0.84–5.22 2.91 0.84–10.1 1.01 0.53–1.90
NA 1.56 1.15–2.13 1.73 1.43–2.09
, PR, HER2+), basal-like (ER, PR, HER2 and CK5/6+ and/or EGFR+).
, PR, HER2+) and triple negative (ER, PR, HER2).
negative (ER, PR and HER2).
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from survival extremes. The strongest HR was observed at a SNP
upstream ARRDC3 gene HR = 1.61 (1.33–1.96, p = 9.5  107). It
was followed by PBX1 HR = 1.28 (1.16–1.43, p = 3.8  106) and
by SNPs located in RORa locus, NTN1 and SYT6 genes.
In contrast, when the authors tried to replicate these results in a
larger set of breast cancer patients unselected for age or survival
extremes they found no association of these SNPs with breast can-
cer prognosis. Moreover, none of them was associated with clinical
predictors of breast cancer prognosis (ER-status, N-stage or
M-stage). These facts limit the reliability of the associations be-
tween these SNPs and breast cancer prognosis [78].
Conclusions
The data from preclinical and epidemiological studies suggest
that the onset of clinical metastases is a biological phenomenon
in which not only participates the genotype of the tumor, but also
the genetic background of the host would be of importance. If this
proposition is true, then certain genetic constitutions would be
more likely to develop metastatic spread, regardless of any other
characteristics of the tumor or in conjunction with certain tumor
phenotypes. However, data from genomic analysis studies, even
those using the GWAS approach, have not given sufﬁcient proof
to support the genetic predisposition model, although this conclu-
sion cannot be ruled out. The limitations of the genomic studies
published to date may be due to the absence of control groups,
or to the fact that certain allelic variants would not be included
in commercial arrays [74]. Nevertheless, another possible explana-
tion might be the selection of cases for study. In complex diseases,
such as cancer, there are multiple phenotypes that are ultimately
responsible for moderate differences in survival of patients. Conse-
quently, when analyzing such diseases, the inclusion of all types of
cases in the sample may lead to the recognition of allelic variants
associated with small changes in the expression of certain features
of the tumor phenotype as the metastatic phenotype. However, the
inclusion in such studies of patients with any outcome could hin-
der the identiﬁcation of other allelic variants that truly determine
the overall expression of the metastatic phenotypes.
A full understanding of the genetic variants involved in the con-
trol of the metastatic dissemination of breast cancer would
undoubtedly lead to far-reaching diagnostic and therapeutic reper-
cussions. First, the accuracy in determining the prognosis in pa-
tients could be enhanced and, as a result, individual tailoring of
complementary adjuvant therapies after surgery might become a
reality. Moreover, it could contribute towards our understanding
of new control pathways that, in turn, will help to identify new
therapeutic targets.
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